These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21918339)

  • 1. [Investigating the incidence of injection-site reactions associated with administration of oxaliplatin into a peripheral vein and management local adverse reactions].
    Hibi S; Tatematsu M; Nishio S; Miyatani M; Tosaki K; Ohara M; Maeda T; Tomita N; Kawai M; Ina K; Oishi K; Muro K
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1447-52. PubMed ID: 21918339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain.
    Kawazoe H; Sumikawa S; Nakauchi K; Yakushijin Y; Yamamoto Y; Watanabe Y; Tanaka A; Araki H
    Int J Clin Pharm; 2017 Dec; 39(6):1291-1297. PubMed ID: 29027645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies.
    Handa S; Kuroiwa R; Miyano M; Shimizu H; Kamei D; Takei H; Sonou H; Yamamoto H; Murayama J; Sato A; Kato Y
    Gan To Kagaku Ryoho; 2016 Aug; 43(8):985-8. PubMed ID: 27539041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Search for Factors Related to Vascular Pain Expression upon Administration of Oxaliplatin into a Peripheral Vein].
    Takagi A; Yonemoto N; Aoyama Y; Touma Y; Kajiwara M; Watanabe K; Miyazaki Y; Koinuma M
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):887-9. PubMed ID: 26197757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of local reactions to oxaliplatin infusions by peripheral versus central venous administration.
    To YY; Sutcliffe KJ; Hoen HM; Swaney RA; Nicholls JD; Crocenzi TS
    J Oncol Pharm Pract; 2016 Apr; 22(2):256-60. PubMed ID: 25762052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk Factors for Oxaliplatin-Induced Phlebitis and Venous Pain, and Evaluation of the Preventive Effect of Preheating with a Hot Compress for Administration of Oxaliplatin].
    Nakauchi K; Kawazoe H; Miyajima R; Waizumi C; Rokkaku Y; Tsuneoka K; Higuchi N; Fujiwara M; Kojima Y; Yakushijin Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(11):1397-400. PubMed ID: 26602398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Etiology and management of venous pain during intravenous administration of oxaliplatin].
    Matsuyama K; Mishima H; Ueno H; Kajihara K; Morioka A; Morimoto S; Yamauchi K; Honda Y; Komori K; Tsujinaka T
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):411-4. PubMed ID: 21403443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain].
    Miyajima R; Kawazoe H; Tsuneoka K; Fujiwara M; Kojima Y; Yakushijin Y
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):537-40. PubMed ID: 23848028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO).
    Hata T; Honda M; Kobayashi M; Toyokawa A; Tsuda M; Tokunaga Y; Takase K; Miyake M; Morita S; Nagata N; Sakamoto J; Gosho M; Mishima H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1209-15. PubMed ID: 26560483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reduction of vascular pain due to drop-infusion of oxaliplatin (L-OHP) in peripheral vein with heated infusion route].
    Yatate M; Kimura M; Iwasaki Y; Kamura M; Yokoi M; Uchitani S; Mizumoto T; Matsushita H
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):589-91. PubMed ID: 22504683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone].
    Shiotsuka Y; Uebuchi M; Hamada S; Morita N; Moriyama A; Yamashita M; Ichikawa Y; Fujii H; Matsuo A; Kuhara H; Ikuta Y; Ikeshima S; Kuramoto M; Fujii K; Shimada S
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1583-6. PubMed ID: 23064078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.
    Yamauchi H; Goto T; Takayoshi K; Sagara K; Uoi M; Kawanabe C; Matsunaga M; Miyoshi T; Uchino K; Misumi N; Nishino T
    Eur J Cancer Care (Engl); 2015; 24(1):111-6. PubMed ID: 24304429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
    Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
    Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain.
    Nagao S; Furihata M; Fukagawa K; Furihata T; Matsuhashi Y; Wada T
    J Infect Chemother; 2017 Jul; 23(7):493-497. PubMed ID: 28285948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
    Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
    Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
    Shao YY; Hu FC; Liang JT; Chiu WT; Cheng AL; Yang CH
    J Formos Med Assoc; 2010 May; 109(5):362-8. PubMed ID: 20497869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
    Cortejoso L; García MI; García-Alfonso P; González-Haba E; Escolar F; Sanjurjo M; López-Fernández LA
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1463-72. PubMed ID: 23543295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule.
    Meyer L; Zuberbier T; Worm M; Oettle H; Riess H
    J Clin Oncol; 2002 Feb; 20(4):1146-7. PubMed ID: 11844841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.